Formulation Development
Outlook Therapeutics Completes Patient Enrollment for Phase 3 Clinical Trial
Outlook Therapeutics, Inc. recently announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab…
Altimmune Announces $3.7 Million in Additional BARDA Funding
Altimmune, Inc. recently announced the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by awarding an…
Cara Therapeutics Enters Commercial License Agreement With Enteris BioPharma
Cara Therapeutics, Inc. recently announced it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to…..
Viral Vectors Expected to Play Pivotal Role in Gene Therapy Pipeline for Neurology Indications
Viral vectors, such as adeno-associated virus (AAV), are expected to play a pivotal role in gene therapies for neurology indications, as this vector type has been found to be the most…..
Q BioMed & ChemVeda Announce Potential Chemotherapeutic Breakthrough
Q BioMed, Inc. and Chemveda Life Sciences recently announce the successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential………
Innovate Biopharmaceuticals Announces First Patient Dosed in the First Phase 3 Clinical Trial
Innovate Biopharmaceuticals, Inc. recently announced it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001. This marks the first time…
Oncologie Announces Clinical Trial Collaboration With Merck
Oncologie, Inc. recently announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the…
Mustang Bio Announces $9.28-Million Grant to Fund Phase 1 Trial
Mustang Bio, Inc. recently announced that City of Hope has received a $9.28-million grant from the California Institute for Regenerative Medicine (CIRM) to fund an…
Preliminary Data Confirm Saphyr’s Potential to Replace Traditional Cytogenetics Methods
Bionano Genomics, Inc. recently announced a summary of results from two key studies presented this week at the 2019 Cancer Genomics Consortium Annual Meeting in…
Prostate Cancer Treatment Moving Toward Personalized Approach With 6 New Drugs in the Pipeline
Although options for prostate cancer have historically been limited, the late-stage prostate cancer pipeline holds promise for the future of this second most common cancer…
Cytovation & SMS-oncology Sign Agreement on Conduct of Phase 1/2 Trial
Cytovation AS and Specialized Medical Services-oncology BV recently announce that SMS-oncology has been selected as the CRO to conduct the Phase 1/2 clinical trial with…
AC Immune Announces Research Collaboration With University of Pennsylvania
AC Immune SA recently announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania (Penn) focused on studying the pathological mechanisms of…..
CureVac Enters Exclusive Collaborative Research Agreement
CureVac AG recently announced it has entered into a Collaborative Research Agreement with Yale University for discovery research into mRNA-based……
Saama & Comprehend to Form Preeminent Clinical Analytics Platform Company
Saama Technologies, Inc. recently announced it has signed a definitive agreement to acquire Comprehend Systems, Inc. to create an exciting, enhanced suite of………..
Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets
Developing ODTs is a worldwide trend. In recent years, new excipients and excipient blends have enabled manufacturers to produce ODTs using conventional equipment, ie, blenders and tablet presses. One such product is GRANFILLER-D………
INmune Bio Reports Positive Preliminary Data from INB03 Phase 1 Clinical Trial
INmune Bio, Inc. recently reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston. INB03 is being developed…
Aquinox Pharmaceuticals & Neoleukin Therapeutics Announce Merger Agreement
Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc. recently announced the two companies entered into a definitive merger agreement under which Aquinox agreed to the acquisition…
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase 3 Study
Celsion Corporation recently announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase 3 Study with…
Eureka Therapeutics Announces Initiation of Phase 1/2 Clinical Trial
Eureka Therapeutics, Inc. recently announced initiation of Phase 1/2 clinical trial of ET140202 ARTEMIS T-cell therapy in liver cancer at City of Hope, a world-renowned…
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study
Oncternal Therapeutics, Inc. recently announced it has opened for enrollment its randomized Phase 2 study of cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib in…
